Lexeo Therapeutics, Inc. Cash And Cash Equivalents At Carrying Value

Quick Answer

Lexeo Therapeutics, Inc. reported Cash And Cash Equivalents At Carrying Value of $63.00 million for the year ending 2025.

  • Lexeo Therapeutics, Inc. showed an increase of +79.9% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
  • This data is from Lexeo Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
  • XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 5 years of available data (2021 to 2025), Lexeo Therapeutics, Inc.'s Cash And Cash Equivalents At Carrying Value has declined by 53.6%.
  • Historical annual values: Fiscal year 2025: $63.00 million | Fiscal year 2024: $35.01 million | Fiscal year 2023: $121.47 million | Fiscal year 2022: $77.34 million | Fiscal year 2021: $135.86 million.
  • Data sourced from SEC EDGAR public filings as of June 23, 2026.

Last verified: